Cargando…

Study of PD-1 Customization and Autoimmune T Cells for Advanced Colorectal Cancer with High MSI Expression

OBJECTIVE: To evaluate the significance of PD-1 customization and autoimmune T-cell therapy for advanced colorectal cancer with high MSI expression. METHODS: One hundred and eight patients with advanced colorectal cancer with high MSI expression admitted to our hospital between August 2019 and Janua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Na, Zhang, Xiaojie, Zhang, Yinsong, Yang, Fang, Zhou, Fengju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357754/ https://www.ncbi.nlm.nih.gov/pubmed/35965619 http://dx.doi.org/10.1155/2022/6390924

Ejemplares similares

Colorectal Carcinogenesis: MSI-H Versus MSI-L
por: Pawlik, Timothy M., et al.
Publicado: (2004)

Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer
por: Heregger, Ronald, et al.
Publicado: (2023)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
por: Oliveira, André F., et al.
Publicado: (2019)

Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis
por: Choi, Jina, et al.
Publicado: (2023)

The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses
por: Cui, Guanglin
Publicado: (2021)

EBV(+) and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8(+) Intratumoral Lymphocytes
por: De Rosa, Simona, et al.
Publicado: (2018)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer
por: Lin, Anqi, et al.
Publicado: (2020)

Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
por: Zhang, Xuan, et al.
Publicado: (2022)

Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer
por: Slik, Khadija, et al.
Publicado: (2017)

Complex pattern of immune evasion in MSI colorectal cancer
por: Ozcan, Mine, et al.
Publicado: (2018)

Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series
por: Zhou, Chengjing, et al.
Publicado: (2021)

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023)

MC1R Is a Prognostic Marker and Its Expression Is Correlated with MSI in Colorectal Cancer
por: Peng, Lixiong, et al.
Publicado: (2021)

B2M and JAK1/2–mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy
por: Zhang, Chenzhi, et al.
Publicado: (2022)

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2022)

Transcriptome of sessile serrated adenoma/polyps is associated with MSI‐high colorectal cancer and decreased expression of CDX2
por: Ohki, Daisuke, et al.
Publicado: (2022)

Immune checkpoints in MSI and CSI colorectal cancers and their translational implications
por: Llosa, Nicolás J, et al.
Publicado: (2013)

A meta-analysis of MSI frequency and race in colorectal cancer
por: Ashktorab, Hassan, et al.
Publicado: (2016)

The role of kras mutations and MSI status in diagnosis of colorectal cancer
por: Shemirani, Atena Irani, et al.
Publicado: (2011)

Diagnostic performance of Idylla MSI test in colorectal cancer biopsies
por: Ukkola, Iiris, et al.
Publicado: (2023)

How I treat MSI cancers with advanced disease
por: Kok, Marleen, et al.
Publicado: (2019)

Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer
por: Hu, Jing, et al.
Publicado: (2016)

Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2023)

Comparing DESI-MSI and MALDI-MSI Mediated Spatial Metabolomics and Their Applications in Cancer Studies
por: He, Michelle Junyi, et al.
Publicado: (2022)

Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan
por: Yoshida, Tsutomu, et al.
Publicado: (2022)

Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
por: Gallois, Claire, et al.
Publicado: (2023)

Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer
por: Ukkola, Iiris, et al.
Publicado: (2021)

Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients
por: Bai, Wenqi, et al.
Publicado: (2019)

MSI-Testing in Hereditary Non-Polyposis Colorectal Carcinoma (HNPCC)
por: Müller, Annegret, et al.
Publicado: (2004)

Functional Polymorphism in the MSI1 Gene Promoter Confers a Decreased Risk of Lung Cancer in Chinese by Reducing MSI1 Expression
por: Liu, Lin, et al.
Publicado: (2018)

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
por: Gou, Miaomiao, et al.
Publicado: (2022)

A novel NGS-based microsatellite instability (MSI) status classifier with 9 loci for colorectal cancer patients
por: Zheng, Kai, et al.
Publicado: (2020)

Mutations in the WTX - gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers
por: Scheel, Silvio K, et al.
Publicado: (2010)

Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)
por: Liao, Ying, et al.
Publicado: (2022)

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
por: Mulet-Margalef, Núria, et al.
Publicado: (2023)

Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond
por: Park, Robin, et al.
Publicado: (2021)

PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report
por: Du, YunYi, et al.
Publicado: (2022)

An Integrative CGH, MSI and Candidate Genes Methylation Analysis of Colorectal Tumors
por: Brim, Hassan, et al.
Publicado: (2014)

Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study
por: Dergham, Ana Paula, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_92jhhv80hn7c8shq9fdo0kpp2h